May 2020

22 May New Results for Patisiran and Givosiran at EAN

We presented new long-term results from the global Open-Label Extension (OLE) study of ONPATTRO^® (patisiran) at the European Academy of Neurology (EAN) Virtual Congress, held May 23-26, 2020. In addition, results were presented from a Phase 3b trial evaluating treatment with patisiran in patients with hATTR amyloidosis with disease progression after receiving an orthotopic liver transplant (post-OLT). A post-hoc analysis of the ENVISION Phase 3 study of GIVLAARI^® (givosiran) was also presented. Read the press release View the patisiran global OLE poster View the patisiran post-OLT poster View the ENVISION post-hoc analysis View the presentation on disease burden and healthcare utilization among patients with acute intermittent porphyria

14 Apr New Clinical Results for Givosiran at EASL

An abstract describing new 12-month interim data from the ongoing ENVISION open-label extension (OLE) study of givosiran in patients with acute hepatic porphyria (AHP) has been published online by the European Association for the Society of the Liver (EASL) on the International Liver Congress™ (ILC 2020) website.  The data will be presented during the ILC 2020 (London, UK) which was rescheduled to August 25-28, 2020 due to the COVID-19 pandemic. View the ENVISION OLE abstract